Inmune Bio (INMB)
NASDAQ:INMB
INMB Stock Chart & Stats
$1.53
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.53
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.15 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)527.96K
Market Cap
$31.90M
Enterprise Value$5.25M
Total Cash (Recent Filing)$27.73M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding26,585,258
10 Day Avg. Volume585,631
30 Day Avg. Volume527,962
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.90
Price to Sales (P/S)6652.75
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue104.97
Enterprise Value/Gross Profit238.56
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$8.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven EfficacyA biomarker-driven enrichment strategy focusing on patients with multiple inflammation-linked markers produced cognitive improvements and reductions in a key neurodegenerative blood biomarker in earlier testing, supporting targeted development efforts.
Financial PositionReported cash resources appear sufficient to fund ongoing clinical programs and regulatory milestones, reducing near-term financing pressure and potential dilution.
Regulatory PathwayFDA alignment on an integrated Phase two/three registration study for XPro creates a clearer development path that could streamline confirmatory testing and support future approval decisions.
Bears Say
Clinical Trial Execution RiskA prior Phase two Alzheimer's trial missing its primary goals raised questions about program robustness and contributed to the share-price pullback, highlighting execution risk for future studies.
Investor Sentiment And VolatilityMarket reaction to the Phase two miss increased investor sensitivity and could amplify stock volatility around upcoming trial readouts and regulatory updates.
Regulatory Approval RiskFailure to meet primary endpoints in earlier testing increases the likelihood that regulators will demand additional confirmatory evidence or limit approval to a narrow subgroup, complicating the path to broad marketing authorization.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.15 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $31.90M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Mar 30, 2026 which is in 3 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Oct 30, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.26.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 5.78%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (455.56% Upside)
$8.50 (455.56% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.23%
12-Months-Change
Fundamentals
Return on Equity
-172.00%
Trailing 12-Months
Asset Growth
-36.80%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.50
▲(455.56% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.17%
Insiders
4.83% Mutual Funds
2.33% Other Institutional Investors
75.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---